{"ticker": {"uuid": "f13208a9-5d26-4454-b1bb-175d72595ff1", "symbol": "RYTM", "name": "Rhythm Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties due to potential self-dealing. Long-term shareholders are encouraged to contact the firm to discuss potential damages and corporate gover", "url": "https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-rhythm-pharmaceuticals-inc-to-contact-law-firm-302831255.html", "source_name": "PR Newswire", "published_at": "2026-07-21T21:10:10", "published_display": "21 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth", "summary": "Rhythm Pharmaceuticals (RYTM) stock is trading within its recent range as the company reports double-digit revenue growth for its rare obesity therapy, setmelanotide. Q1 2026 revenue reached $29 million, up 38% year-over-year, driven by increased patient uptake. While the company", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/rytm-stock-trades-around-recent-range-as-rhythm-pharmaceuticals-highlights/69825157", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T19:14:00", "published_display": "21 Jul 2026 19:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026", "summary": "Rhythm Pharmaceuticals, Inc. announced it will host a conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. The company is a commercial-stage biopharmaceutical firm focused on r", "url": "https://www.manilatimes.net/2026/07/21/tmt-newswire/globenewswire/rhythm-pharmaceuticals-to-reportsecondquarter2026financial-results-ontuesdayaugust-4-2026/2388406/amp", "source_name": "The Manila Times", "published_at": "2026-07-21T12:10:12", "published_display": "21 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals schedules live Q2 results webcast Aug. 4", "summary": "Rhythm Pharmaceuticals (Nasdaq: RYTM) will report its second-quarter 2026 financial results and provide a corporate update during a live conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET. The company, a commercial-stage biopharmaceutical firm, focuses on rar", "url": "https://www.stocktitan.net/news/RYTM/rhythm-pharmaceuticals-to-report-second-quarter-2026-financial-j82v9nqcptak.html", "source_name": "Stock Titan", "published_at": "2026-07-21T12:10:12", "published_display": "21 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside", "summary": "Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focusing on treatments for rare neuroendocrine diseases, driving investor interest with strong analyst ratings and growth potential. Despite current negative EPS and high R&D costs, its 83.8% revenue growth and fl", "url": "https://www.directorstalkinterviews.com/rhythm-pharmaceuticals-inc-rytm-investor-outlook-strong-buy-ratings-signal-potential-31-upside/4121256869", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-21T01:10:10", "published_display": "21 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders", "summary": "Kuehn Law, PLLC is investigating officers and directors of Rhythm Pharmaceuticals, Inc. for alleged breaches of fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms. Long-term shareholders ar", "url": "https://pluang.com/en/news-feed/kuehn-law-ajakan-pemegang-saham-rhythm-pharmaceuticals-hubungi-firma-hukum", "source_name": "Pluang", "published_at": "2026-07-17T01:13:35", "published_display": "17 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity", "summary": "Rhythm Pharmaceuticals' drug, setmelanotide, shows promising Phase 3 results for acquired hypothalamic obesity (HO), targeting a potential FDA approval by March 20, 2026. This condition represents a significant unmet medical need with a substantial global patient population. Anal", "url": "https://www.kavout.com/market-lens/is-rhythm-pharmaceuticals-poised-for-a-breakthrough-in-hypothalamic-obesity", "source_name": "Kavout | AI", "published_at": "2026-07-16T23:39:22", "published_display": "16 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155", "summary": "Wells Fargo has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its price target at $155. This continued positive outlook suggests the firm sees sustained value and growth potential for the pharmaceutical company.", "url": "https://www.moomoo.com/news/post/73074190/wells-fargo-maintains-rhythm-pharmaceuticals-rytmus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-16T13:10:13", "published_display": "16 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)?", "summary": "Rhythm Pharmaceuticals' pivotal Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity have been published in The New England Journal of Medicine, reinforcing its role as a targeted therapy. While this validates the drug, the company's investment narra", "url": "https://www.sahmcapital.com/news/content/does-nejm-validated-transcend-data-on-setmelanotide-reshape-the-bull-case-for-rhythm-pharmaceuticals-rytm-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T22:47:23", "published_display": "14 Jul 2026 22:47", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. \u2013 BMV:RYTM", "summary": "This article provides the enterprise value to revenue forward metric for Rhythm Pharmaceuticals, Inc. (BMV:RYTM). It is presented on TradingView, a financial platform offering various market data and analysis tools. The information indicates the financial metric as of the specifi", "url": "https://www.tradingview.com/symbols/BMV-RYTM/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T22:47:23", "published_display": "14 Jul 2026 22:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data By Investing.com", "summary": "Citizens has reaffirmed its Market Outperform rating and $155 price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) based on strong Imcivree launch data, particularly in hypothalamic obesity. Endocrinologist surveys suggest better-than-expected sales, leading Citizens to raise it", "url": "https://za.investing.com/news/stock-market-news/citizens-reiterates-rhythm-pharmaceuticals-stock-rating-on-strong-imcivree-launch-data-93CH-4367463", "source_name": "Investing.com South Africa", "published_at": "2026-07-14T10:40:43", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data", "summary": "Citizens has reiterated a Market Outperform rating and $155.00 price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) due to strong Imcivree launch data. A recent endocrinologist survey shows the drug performing well in hypothalamic obesity, suggesting potential for a strong sales", "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-rhythm-pharmaceuticals-stock-rating-on-strong-imcivree-launch-data-93CH-4789979", "source_name": "Investing.com", "published_at": "2026-07-14T09:52:05", "published_display": "14 Jul 2026 09:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology", "summary": "Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company focusing on rare neuroendocrine diseases, notably with its lead product IMCIVREE. The company shows strong market potential with a $7.44 billion market cap, significant revenue growth of 83.80%, and positive analyst sen", "url": "https://www.directorstalkinterviews.com/rhythm-pharmaceuticals-inc-rytm-stock-analysis-exploring-a-28-91-upside-potential-in-biotechnology/4121256211", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:11:15", "published_display": "13 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Rhythm Pharmaceuticals, Inc. \u2013 NASDAQ:RYTM", "summary": "This article provides financial data for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), specifically focusing on its forward price-to-earnings ratio. It indicates that the company is listed on the Nasdaq Stock Market and that the market was closed with no trades at the time of publ", "url": "https://www.tradingview.com/symbols/NASDAQ-RYTM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T17:40:50", "published_display": "12 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals (RYTM) On TRANSCEND And New Approvals, Buying Opportunity Or Priced In?", "summary": "Rhythm Pharmaceuticals (RYTM) is gaining attention after positive Phase 3 TRANSCEND trial results for setmelanotide and recent US and European regulatory approvals. Despite a significant stock price increase, analysts believe the stock is 18% undervalued, with a fair value of $13", "url": "https://www.sahmcapital.com/news/content/rhythm-pharmaceuticals-rytm-on-transcend-and-new-approvals-buying-opportunity-or-priced-in-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-09T21:13:14", "published_display": "09 Jul 2026 21:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. \u2013 XETR:1RV", "summary": "This article focuses on the enterprise value to revenue forward for Rhythm Pharmaceuticals, Inc. (XETR:1RV). It is a financial overview of the company, likely providing data or analysis related to this specific valuation metric. The content was provided by FactSet Research System", "url": "https://www.tradingview.com/symbols/XETR-1RV/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T16:41:07", "published_display": "09 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces The New England Journal of", "summary": "Rhythm Pharmaceuticals announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for acquired hypothalamic obesity were published in The New England Journal of Medicine. The study demonstrated robust improvements in weight and hunger, with setmelano", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324480/0/en/rhythm-pharmaceuticals-announces-the-new-england-journal-of-medicine-publication-of-phase-3-transcend-trial-results-in-acquired-hypothalamic-obesity.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T09:10:49", "published_display": "09 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine.", "summary": "Rhythm Pharmaceuticals Inc. announced the publication of its Phase 3 Transcend clinical trial results for acquired hypothalamic obesity in The New England Journal of Medicine. This publication highlights the efficacy and safety of their investigational therapy for severe obesity ", "url": "https://www.bitget.com/amp/news/detail/12560605496326", "source_name": "Bitget", "published_at": "2026-07-09T08:41:07", "published_display": "09 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity", "summary": "Rhythm Pharmaceuticals announced the publication of its Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity in The New England Journal of Medicine. The study demonstrated significant reductions in BMI and improvements in hunger in patients, leading ", "url": "https://ca.finance.yahoo.com/news/rhythm-pharmaceuticals-announces-england-journal-210700817.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-09T08:41:07", "published_display": "09 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity", "summary": "Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) published results from its pivotal Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity. The study, the largest and longest placebo-controlled trial for this condition, demonstr", "url": "https://www.quiverquant.com/news/Rhythm+Pharmaceuticals+Announces+NEJM+Publication+of+Phase+3+TRANSCEND+Trial+Results+for+Setmelanotide+in+Acquired+Hypothalamic+Obesity", "source_name": "Quiver Quantitative", "published_at": "2026-07-08T21:20:00", "published_display": "08 Jul 2026 21:20", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating", "summary": "NULL", "url": "https://www.moomoo.com/news/post/72586221/rbc-capital-adjusts-rhythm-pharmaceuticals-price-target-to-141-from", "source_name": "Moomoo", "published_at": "2026-07-08T08:41:07", "published_display": "08 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm\u2019s obesity drug data lands in NEJM after 52-week Phase 3 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRy1vemRhWDhLYm9VbkU3M1BGcEpXY1l0bWduTzI1d2w5MzhldzQ0ZVZaYjJyU2hVMm9Ld2hxVWdlNmtVYTJTLXhMbHgwdU1WMTNPY3ZpMHI2bDlrSmNKTUJXMFR3LWVzV3lWU1hEc0V3ZnV6eUQwOFkyb3VNYlBTLVBEaVU4cUsteHJIY3VpUVp5NEhQN2ZzLWlzMFQ2OFAtMUEzY0U0dnNyOGNSOGtxdUJMdEhHUXZadmJucDBZVmY?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM", "summary": "Rhythm Pharmaceuticals will present new data on acquired hypothalamic obesity (AHO) at the Pediatric Endocrine Society Annual Meeting. These presentations will include real-world data highlighting the impact of AHO on patients and families, as well as an analysis of the genetic c", "url": "https://www.moomoo.com/news/post/69339826/rhythm-pharmaceuticals-announces-new-data-presentations-in-acquired-hypothalamic-obesity?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-06T20:13:15", "published_display": "06 Jul 2026 20:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rhythm Pharmaceuticals, Inc. \u2013 NASDAQ:RYTM", "summary": "This page displays financial information for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) on TradingView, specifically focusing on its price-to-sales forward metric. The content includes an overview of the company's market data, financial health, and other related services offered", "url": "https://www.tradingview.com/symbols/NASDAQ-RYTM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T12:39:43", "published_display": "05 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RYTM - Rhythm Pharmaceuticals Inc Options", "summary": "This article provides a detailed financial overview of Rhythm Pharmaceuticals Inc (RYTM), including its stock performance, key financial metrics, and analyst ratings. It covers market capitalization, sales, income, various ratios, and insider/institutional ownership, alongside re", "url": "https://finviz.com/quote.ashx?t=RYTM&p=d&ty=oc&ov=plot", "source_name": "Finviz", "published_at": "2026-07-04T20:13:15", "published_display": "04 Jul 2026 20:13", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals announces public offering of common stock", "summary": "Rhythm Pharmaceuticals has announced a public offering of its common stock. The company is making this offering to raise capital. Further details about the offering size or expected use of proceeds were not provided in this snippet.", "url": "https://www.msn.com/en-us/money/savingandinvesting/rhythm-pharmaceuticals-announces-public-offering-of-common-stock/ar-AA1Ii1t2?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-04T01:09:25", "published_display": "04 Jul 2026 01:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript", "summary": "Rhythm Pharmaceuticals Inc. will discuss interim six-month Phase 2 results for Setmelanotide during an upcoming call. The transcript indicates the call will feature a presentation followed by a question-and-answer session, where participants can ask questions by pressing star 11.", "url": "https://www.gurufocus.com/stock/RYTM/transcripts/8915603", "source_name": "GuruFocus", "published_at": "2026-07-03T20:10:13", "published_display": "03 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNanBLVzRFMXE1Q0NocTNSZllJRHBGdVBkalBIc3J3OTBzWVhHd25aWFVvb2d6a1c5Ykc5bDJra1dBNW5pZUhHNEgtY1hpZFJ1a2trWTJ5NnRFcl9QdEpCbFJZOTlqclA5UlItcndiUWhrZGxvLTgxakdvcElmeGJVMmN4N0twU0F5YmVKTmdMNmxwQlVLeHJTTldoUnBwOWc?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Stock On Fire: Up 26% With 10-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxObER3WU5JOHdJQjc5ZXJ3dEdXeU9lTU5UMEJTZXZ3OVNFSlpKTGg2ZzBrVDJrLWxrSFJsVHNuMEctVHlFdC1kRDBtZUJKMXN4SlZ4N3V1UnlVcEJvMF9NX2NuSUg3VmNGc0pobWhVTVRKWnpidEliSDNWT01sT256bTdkYVdxaVhpWW41VHJRTXdyanQ1Tmt0NHJyZ0xTYkZtZjhWdnZsMC1SMkJMRjNDODQ4Y3RXUE41Q1ZmWDBYWWxpTUtDcEkxMXV3?oc=5", "source_name": "Trefis", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZVVjLTdLQnZiQ2J3LVRkVGpTUW91TEtzaHVvaVVWNVMzSzhVbE1ucE91ZnI0VzNqQlhZZVFRU0Z0eUFSNVRmdW0tWkZha0FaZnFGMVZHZUQ0cmdjNkZldzhNTkppSTFFUld0aGFsN3ppbFd3MmM5ZWVmY0xPSV9ITlBYd2k1dW9Bay1xcV9fNXpIVzB4blFCQ0FSQkp0bTlzZTNhMXpOYklUUWNXSjdtZmI2UVl3b1hRX2hHag?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals(RYTM.US) Director Sells US$3.71 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQazRWelIxUmR3akl0X0RCa3ZSVTEteDhmZ0JwV1NYd2xkampINmNQT0c0TGNyRTFpdHRnQklsVmJwLTRKZmJkSS1KNjd6Mk55alZjMEdXWU1lTENlY1hmdVJ3d1RYZnU0NFF1aGxuaVlaM0lMaE5GX01VNWZxQXFrVDFsRFZ0NFowMTdEbmFOWHlFRU55TEZ5ZTdNTVB0eGJaSm9uRVRYSXc?oc=5", "source_name": "Moomoo", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdXRYT2Q3RldYYkE2dnZhaWRFd2ZnV3Zyd3lMa3JHZk5iT2l4eHJIbTZkMEFNLTlTeUtzS0VGSzgtZkVvZ3J5dU5KWmNyMWpVZTdwdjVZSkZiZEphNEhEc2RIZVFKVG5CUjNwT25NbHlNRVY4blktX2xnZ01DV3NNUWIwYkVBckVSd2RRVjR1T2QwTWZsNmg4QUhwNzBqZjdDZkkxQjVuRGd3bENzMTdyMlMyY2RrTTFTYWdxRA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQU0hTczJJLUJRRndBd1BlWkYzRFZUWjhodDI4dGRWX05TOVJtVjN0dWJxVUI0YnVrbnpLMGl0czRzQ3ZEaVU2bXRjSVJESVJJSWNRemxuTks0RVhIZDVSN0xOUnlnbFV1R0ZFN3Z5SzJ4U3N2R1lqbmxrQWlPbXJueGItMTVVVTNpaEJESTF4OUhzSXNWaGpCckdMUUkxdkxOcWlKd0dIMnRjU1U1ZkJ2ZzNXTWVrMDN0N3Z2Z3lDc0I?oc=5", "source_name": "Trefis", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Rhythm Pharmaceuticals (RYTM) \u2019s New Data Help Patients With a Rare Hunger Disorder?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rhythm-pharmaceuticals-rytm-data-help-141500938.html", "source_name": "Insider Monkey", "published_at": "2026-06-22T14:15:00+00:00", "published_display": "22 Jun 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RHYTHM PHARMACEUTICALS, INC. SEC Filing (Jun 22, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOSG5VLWZSY0FpMW5hMU5uVW80eUFSMEE2UGI5N0RubnYzLTRFbUI4VlZmS3ZBNlZ6amVONTBJaVNGTGV4bWlwUzF0dmN1NVRydmcxZkpwb1g4dkNWNHNuWVhBM1E3X25FWnhsOVJ3Ti1LaTU2UDMxelJXZERQNWZvQlh0cmVDZUJ5TkFsY29MYkZwX3RkOWktaUlPRWJsczJVRWJSYW93?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity", "summary": "", "url": "https://finance.yahoo.com/m/a04f1a26-d944-3d53-a27d-549494a3b05b/rhythm-pharmaceuticals-posts.html", "source_name": "Proactive", "published_at": "2026-06-16T15:37:00+00:00", "published_display": "16 Jun 2026 15:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rhythm-pharmaceuticals-announces-multiple-data-200100919.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T20:01:00+00:00", "published_display": "15 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Rhythm Pharma Stock Jumping Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOTUl1SExJOWVCQzdnOW1TU1VHZXBwVmtoVV9aSWptQUxvTlV6enNCY1NxdXNibmJlc21fdXRoaVV1WjlPZVBIdURNTDRoTTMxX3c1YnZpcU1SVWtWaXBPbkp2eDhPVkJrZzVMYWVsVXU1WmMzaGVGeTNCTFNPZGpZRVZnVU9nbkRrNjJqNW5sUkZXc2V1emFKYTBrdXdtZw?oc=5", "source_name": "Benzinga", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rhythm-pharmaceuticals-presents-positive-interim-120100510.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T12:01:00+00:00", "published_display": "13 Jun 2026 12:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQTlc5M25rMmZON0ZGMGxjMXI0MUk0dXpvbnFweVpXSVhKYXpDUXBpcnZsRjlEaGUtWk43bWs0NG0wLWllX0FkYnAtX0FRRUpsX1dUbEZsWTlSSFY1QzczeGNxR3p1VU9FandiWmpER1FGTlppdGFYOUw5SmNFeHFNdC1iOXV0ejRDZlQ2NUdUdW44aVZlQ3A5RmdBYzM1M2NjdGZPNmUxTUhyNXJScVhpaUVqZlI1aWxfM0lqMzEyWHo2dVlKM3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOalFlbWJoWnRObW9hYzlEZmZ6ODloSWk3MkVHOGdQc1FNVndqQ3JnVmM3MjFvSERaQkZEclVBYkJJVGUtVFZSSkUxX3hfejVJTHlad0dkMjZKUFFNZHVEemNzNUpzRDdtVks2bXl3WDQwUUdybDlPa1RtREl5VXdOT2VXbF8wcTVuX3IyMGx2eEtZN2FNX2E1YldQYk5BU0JER3pkdjhn?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its Recent Share Price Surge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Q1 2026 Earnings: Stock Rises 8% on Imcivree Revenue Beat - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPLUoweEFBQzNaQl9WTkVDeHRNM1NuR0ZYeTk3WHNTcHhvR1FjY2pPbkd4VGdGdWd6SS1PaGdyWmFRZkdkMktaWnpjVjJQcXpqTUppQWJacnpmbk9MZldhUGd0T0JycVZmS1Z6UzgzT1pBTFcwVlJZbWp5MnJoUTJTTFprc00tTEpDdzRuUEZpTHQxVFNBMlhtbkpsR3lFZEVRYnpjNENTSFIxZWg3Vnd2eDB3?oc=5", "source_name": "IndexBox", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm CEO to speak at Bank of America healthcare conference May 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOWldWTjVLSmVuVDNRajl3THZfVmFCTXMwQ2xLWTNRZmw0VWR0OFpOMXZUSVp3YXg0VVR3Uy1UTzEtNWpqVmhzNVdjRVZ1YUNjNkNIWmZiQUpSSTFOZnlvNlRyRGFpVGJ6Nk9NVzRsbGxKYVNzVGJ4QVc4YVo5R2VJcTNDUHdQYXRNR01aeFYxSnZKTHhNaEF1QnJHODdITkxNLWJGcHVwdlVQbmVhcGExeE9oa3BDU2VGSHFJSFdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPMUNrcGFWTXluSWtGUEszTzR5UzlVLW80X1c3Y3ViQkR0UW9RWDNvY1BxZjQ1NjdFOWZBUThvUHRZRnBROFp2QzZKLXFIbjhXdXpVQTRNT1gwSEF6T1dfNGRiNHQ3YTl4VktLNG0xVjc3YU5ncDBab2VKVkVGamFWLTR1aXJta0VBTUczVUxuckpYR0VvOG9ncjBLQ0lPdzBzMV9FaXJBeDhzSFRx?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPbS10bWNXQV9JWnA1TWhpTzhmejZxTG1nS1hPanRoVzh2dHpFY3dySExrS3I0V0FsQW80bzNCUzNRbXZCc3g0RG8yTUhCM2RpY240emMzS0xZNG9neU5fekFXb2dMRzNSemttMnYzN0tDVDRSMmI3UmtBYzY3UjRhMXF5ajJwSDl2LTVnZ2lWTjRMdmRLb09FaFF2cjAzZEZfZUM0MFdGeFhqa3BDaUtocVQwUEthRW8wMkoyUHlEb2xaVXlUOFhJQ0xxdk1UYUtlYmNaMm1WSFBJdkxTa2lDUFRHbFI1amlwVmlLZktJWEw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOQkViaHNXNkhrZW9YMmZvbGdsa2o5X0pLaVVpOXlKQ3lCMlE1bDUzTkx1ZnBNRk1uc0hiSnJhUVpNbWZILVNudFotNlhISTY1SHNXOVQ1UldtUDBxeXpjR0pabV8tZUxZb094S1I4NE1fR3NUR0hZV3NWdUF4Y0pHRG9sd24wbWVVRlB3QlJLR2NiY3ZFc1J0MGJ3RjI3QU95R3JpRlU5OWRuZjJGS1pSdEs4bm4?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQZjdSMGR4aUtzbnN3RWdoV1hDZlVoWV9XdWFKckZYRldpenVpSFF6M2l2UEVKV1lrRGwzSE93M2dfOFNGenQ5cHYxcGs5UHQyVlR6cXh0TEtibGR3eDg0akhEUmVPcWNEcHhCLUR6d0w2TFNyX0t0WXFBeFNMQXFIc256REp2WDZDRzEzLTBiRkZoUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxNRGwxUzVxcHFDcTdBLXNvVjcwdG9PLU1Pdmpram1RUHdHOFdoRFd4Vm1xM0xhVEszcTZiTE5zSTZ4WGZVbWtaUW9ucFR4aWxqLThES19DUXdkdlBuUXlDS3dlUmh6X1Brdjc4cjhxMUJnV25kbVBEUk5fdHdNYmZNZ0pod0lhOVpiVXFyWnJEZ3NMUXItb051TjlGYldYRmswZURTUEpvUUwwMm9sSFR1N3J3MlExa08wVDhVOWxwSGhZMzU2ZWtrSmltd01HNXRXbGg0M1dqRUtmZjA5SldHcnFMdjZLYTJJbUlwMUZ2Vzd4UEhEajNiajN4WVBFY1k3?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q2 2025 Rhythm Pharmaceuticals Inc Earnings Call Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5EQWFaQ0pmbWdqWWdGNnVsMHFabFhhQlBaUU5tbk55U1BtblpzSENKZm5oVzQ4OFl2Z0k0NDBfd2otaVl1Ml9IRlFyeWJUc3Q2VHpNTkk3RkY5TnFDbkhONGl1Z1o0X2JXcVVQeQ?oc=5", "source_name": "GuruFocus", "published_at": "2025-08-05T07:00:00+00:00", "published_display": "05 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties due to potential self-dealing. Long-term shareholders are encouraged to contact the firm to discuss potential damages and corporate gover", "url": "https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-rhythm-pharmaceuticals-inc-to-contact-law-firm-302831255.html", "source_name": "PR Newswire", "published_at": "2026-07-21T21:10:10", "published_display": "21 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth", "summary": "Rhythm Pharmaceuticals (RYTM) stock is trading within its recent range as the company reports double-digit revenue growth for its rare obesity therapy, setmelanotide. Q1 2026 revenue reached $29 million, up 38% year-over-year, driven by increased patient uptake. While the company", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/rytm-stock-trades-around-recent-range-as-rhythm-pharmaceuticals-highlights/69825157", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T19:14:00", "published_display": "21 Jul 2026 19:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026", "summary": "Rhythm Pharmaceuticals, Inc. announced it will host a conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. The company is a commercial-stage biopharmaceutical firm focused on r", "url": "https://www.manilatimes.net/2026/07/21/tmt-newswire/globenewswire/rhythm-pharmaceuticals-to-reportsecondquarter2026financial-results-ontuesdayaugust-4-2026/2388406/amp", "source_name": "The Manila Times", "published_at": "2026-07-21T12:10:12", "published_display": "21 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals schedules live Q2 results webcast Aug. 4", "summary": "Rhythm Pharmaceuticals (Nasdaq: RYTM) will report its second-quarter 2026 financial results and provide a corporate update during a live conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET. The company, a commercial-stage biopharmaceutical firm, focuses on rar", "url": "https://www.stocktitan.net/news/RYTM/rhythm-pharmaceuticals-to-report-second-quarter-2026-financial-j82v9nqcptak.html", "source_name": "Stock Titan", "published_at": "2026-07-21T12:10:12", "published_display": "21 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside", "summary": "Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focusing on treatments for rare neuroendocrine diseases, driving investor interest with strong analyst ratings and growth potential. Despite current negative EPS and high R&D costs, its 83.8% revenue growth and fl", "url": "https://www.directorstalkinterviews.com/rhythm-pharmaceuticals-inc-rytm-investor-outlook-strong-buy-ratings-signal-potential-31-upside/4121256869", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-21T01:10:10", "published_display": "21 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders", "summary": "Kuehn Law, PLLC is investigating officers and directors of Rhythm Pharmaceuticals, Inc. for alleged breaches of fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms. Long-term shareholders ar", "url": "https://pluang.com/en/news-feed/kuehn-law-ajakan-pemegang-saham-rhythm-pharmaceuticals-hubungi-firma-hukum", "source_name": "Pluang", "published_at": "2026-07-17T01:13:35", "published_display": "17 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity", "summary": "Rhythm Pharmaceuticals' drug, setmelanotide, shows promising Phase 3 results for acquired hypothalamic obesity (HO), targeting a potential FDA approval by March 20, 2026. This condition represents a significant unmet medical need with a substantial global patient population. Anal", "url": "https://www.kavout.com/market-lens/is-rhythm-pharmaceuticals-poised-for-a-breakthrough-in-hypothalamic-obesity", "source_name": "Kavout | AI", "published_at": "2026-07-16T23:39:22", "published_display": "16 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155", "summary": "Wells Fargo has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its price target at $155. This continued positive outlook suggests the firm sees sustained value and growth potential for the pharmaceutical company.", "url": "https://www.moomoo.com/news/post/73074190/wells-fargo-maintains-rhythm-pharmaceuticals-rytmus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-16T13:10:13", "published_display": "16 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)?", "summary": "Rhythm Pharmaceuticals' pivotal Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity have been published in The New England Journal of Medicine, reinforcing its role as a targeted therapy. While this validates the drug, the company's investment narra", "url": "https://www.sahmcapital.com/news/content/does-nejm-validated-transcend-data-on-setmelanotide-reshape-the-bull-case-for-rhythm-pharmaceuticals-rytm-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T22:47:23", "published_display": "14 Jul 2026 22:47", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. \u2013 BMV:RYTM", "summary": "This article provides the enterprise value to revenue forward metric for Rhythm Pharmaceuticals, Inc. (BMV:RYTM). It is presented on TradingView, a financial platform offering various market data and analysis tools. The information indicates the financial metric as of the specifi", "url": "https://www.tradingview.com/symbols/BMV-RYTM/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T22:47:23", "published_display": "14 Jul 2026 22:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data By Investing.com", "summary": "Citizens has reaffirmed its Market Outperform rating and $155 price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) based on strong Imcivree launch data, particularly in hypothalamic obesity. Endocrinologist surveys suggest better-than-expected sales, leading Citizens to raise it", "url": "https://za.investing.com/news/stock-market-news/citizens-reiterates-rhythm-pharmaceuticals-stock-rating-on-strong-imcivree-launch-data-93CH-4367463", "source_name": "Investing.com South Africa", "published_at": "2026-07-14T10:40:43", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data", "summary": "Citizens has reiterated a Market Outperform rating and $155.00 price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) due to strong Imcivree launch data. A recent endocrinologist survey shows the drug performing well in hypothalamic obesity, suggesting potential for a strong sales", "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-rhythm-pharmaceuticals-stock-rating-on-strong-imcivree-launch-data-93CH-4789979", "source_name": "Investing.com", "published_at": "2026-07-14T09:52:05", "published_display": "14 Jul 2026 09:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology", "summary": "Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company focusing on rare neuroendocrine diseases, notably with its lead product IMCIVREE. The company shows strong market potential with a $7.44 billion market cap, significant revenue growth of 83.80%, and positive analyst sen", "url": "https://www.directorstalkinterviews.com/rhythm-pharmaceuticals-inc-rytm-stock-analysis-exploring-a-28-91-upside-potential-in-biotechnology/4121256211", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:11:15", "published_display": "13 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rhythm Pharmaceuticals, Inc. \u2013 NASDAQ:RYTM", "summary": "This article provides financial data for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), specifically focusing on its forward price-to-earnings ratio. It indicates that the company is listed on the Nasdaq Stock Market and that the market was closed with no trades at the time of publ", "url": "https://www.tradingview.com/symbols/NASDAQ-RYTM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T17:40:50", "published_display": "12 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals (RYTM) On TRANSCEND And New Approvals, Buying Opportunity Or Priced In?", "summary": "Rhythm Pharmaceuticals (RYTM) is gaining attention after positive Phase 3 TRANSCEND trial results for setmelanotide and recent US and European regulatory approvals. Despite a significant stock price increase, analysts believe the stock is 18% undervalued, with a fair value of $13", "url": "https://www.sahmcapital.com/news/content/rhythm-pharmaceuticals-rytm-on-transcend-and-new-approvals-buying-opportunity-or-priced-in-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-09T21:13:14", "published_display": "09 Jul 2026 21:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. \u2013 XETR:1RV", "summary": "This article focuses on the enterprise value to revenue forward for Rhythm Pharmaceuticals, Inc. (XETR:1RV). It is a financial overview of the company, likely providing data or analysis related to this specific valuation metric. The content was provided by FactSet Research System", "url": "https://www.tradingview.com/symbols/XETR-1RV/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T16:41:07", "published_display": "09 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces The New England Journal of", "summary": "Rhythm Pharmaceuticals announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for acquired hypothalamic obesity were published in The New England Journal of Medicine. The study demonstrated robust improvements in weight and hunger, with setmelano", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324480/0/en/rhythm-pharmaceuticals-announces-the-new-england-journal-of-medicine-publication-of-phase-3-transcend-trial-results-in-acquired-hypothalamic-obesity.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T09:10:49", "published_display": "09 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine.", "summary": "Rhythm Pharmaceuticals Inc. announced the publication of its Phase 3 Transcend clinical trial results for acquired hypothalamic obesity in The New England Journal of Medicine. This publication highlights the efficacy and safety of their investigational therapy for severe obesity ", "url": "https://www.bitget.com/amp/news/detail/12560605496326", "source_name": "Bitget", "published_at": "2026-07-09T08:41:07", "published_display": "09 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity", "summary": "Rhythm Pharmaceuticals announced the publication of its Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity in The New England Journal of Medicine. The study demonstrated significant reductions in BMI and improvements in hunger in patients, leading ", "url": "https://ca.finance.yahoo.com/news/rhythm-pharmaceuticals-announces-england-journal-210700817.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-09T08:41:07", "published_display": "09 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity", "summary": "Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) published results from its pivotal Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity. The study, the largest and longest placebo-controlled trial for this condition, demonstr", "url": "https://www.quiverquant.com/news/Rhythm+Pharmaceuticals+Announces+NEJM+Publication+of+Phase+3+TRANSCEND+Trial+Results+for+Setmelanotide+in+Acquired+Hypothalamic+Obesity", "source_name": "Quiver Quantitative", "published_at": "2026-07-08T21:20:00", "published_display": "08 Jul 2026 21:20", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating", "summary": "NULL", "url": "https://www.moomoo.com/news/post/72586221/rbc-capital-adjusts-rhythm-pharmaceuticals-price-target-to-141-from", "source_name": "Moomoo", "published_at": "2026-07-08T08:41:07", "published_display": "08 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm\u2019s obesity drug data lands in NEJM after 52-week Phase 3 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRy1vemRhWDhLYm9VbkU3M1BGcEpXY1l0bWduTzI1d2w5MzhldzQ0ZVZaYjJyU2hVMm9Ld2hxVWdlNmtVYTJTLXhMbHgwdU1WMTNPY3ZpMHI2bDlrSmNKTUJXMFR3LWVzV3lWU1hEc0V3ZnV6eUQwOFkyb3VNYlBTLVBEaVU4cUsteHJIY3VpUVp5NEhQN2ZzLWlzMFQ2OFAtMUEzY0U0dnNyOGNSOGtxdUJMdEhHUXZadmJucDBZVmY?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM", "summary": "Rhythm Pharmaceuticals will present new data on acquired hypothalamic obesity (AHO) at the Pediatric Endocrine Society Annual Meeting. These presentations will include real-world data highlighting the impact of AHO on patients and families, as well as an analysis of the genetic c", "url": "https://www.moomoo.com/news/post/69339826/rhythm-pharmaceuticals-announces-new-data-presentations-in-acquired-hypothalamic-obesity?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-06T20:13:15", "published_display": "06 Jul 2026 20:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rhythm Pharmaceuticals, Inc. \u2013 NASDAQ:RYTM", "summary": "This page displays financial information for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) on TradingView, specifically focusing on its price-to-sales forward metric. The content includes an overview of the company's market data, financial health, and other related services offered", "url": "https://www.tradingview.com/symbols/NASDAQ-RYTM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T12:39:43", "published_display": "05 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RYTM - Rhythm Pharmaceuticals Inc Options", "summary": "This article provides a detailed financial overview of Rhythm Pharmaceuticals Inc (RYTM), including its stock performance, key financial metrics, and analyst ratings. It covers market capitalization, sales, income, various ratios, and insider/institutional ownership, alongside re", "url": "https://finviz.com/quote.ashx?t=RYTM&p=d&ty=oc&ov=plot", "source_name": "Finviz", "published_at": "2026-07-04T20:13:15", "published_display": "04 Jul 2026 20:13", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals announces public offering of common stock", "summary": "Rhythm Pharmaceuticals has announced a public offering of its common stock. The company is making this offering to raise capital. Further details about the offering size or expected use of proceeds were not provided in this snippet.", "url": "https://www.msn.com/en-us/money/savingandinvesting/rhythm-pharmaceuticals-announces-public-offering-of-common-stock/ar-AA1Ii1t2?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-04T01:09:25", "published_display": "04 Jul 2026 01:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript", "summary": "Rhythm Pharmaceuticals Inc. will discuss interim six-month Phase 2 results for Setmelanotide during an upcoming call. The transcript indicates the call will feature a presentation followed by a question-and-answer session, where participants can ask questions by pressing star 11.", "url": "https://www.gurufocus.com/stock/RYTM/transcripts/8915603", "source_name": "GuruFocus", "published_at": "2026-07-03T20:10:13", "published_display": "03 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNanBLVzRFMXE1Q0NocTNSZllJRHBGdVBkalBIc3J3OTBzWVhHd25aWFVvb2d6a1c5Ykc5bDJra1dBNW5pZUhHNEgtY1hpZFJ1a2trWTJ5NnRFcl9QdEpCbFJZOTlqclA5UlItcndiUWhrZGxvLTgxakdvcElmeGJVMmN4N0twU0F5YmVKTmdMNmxwQlVLeHJTTldoUnBwOWc?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Stock On Fire: Up 26% With 10-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxObER3WU5JOHdJQjc5ZXJ3dEdXeU9lTU5UMEJTZXZ3OVNFSlpKTGg2ZzBrVDJrLWxrSFJsVHNuMEctVHlFdC1kRDBtZUJKMXN4SlZ4N3V1UnlVcEJvMF9NX2NuSUg3VmNGc0pobWhVTVRKWnpidEliSDNWT01sT256bTdkYVdxaVhpWW41VHJRTXdyanQ1Tmt0NHJyZ0xTYkZtZjhWdnZsMC1SMkJMRjNDODQ4Y3RXUE41Q1ZmWDBYWWxpTUtDcEkxMXV3?oc=5", "source_name": "Trefis", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZVVjLTdLQnZiQ2J3LVRkVGpTUW91TEtzaHVvaVVWNVMzSzhVbE1ucE91ZnI0VzNqQlhZZVFRU0Z0eUFSNVRmdW0tWkZha0FaZnFGMVZHZUQ0cmdjNkZldzhNTkppSTFFUld0aGFsN3ppbFd3MmM5ZWVmY0xPSV9ITlBYd2k1dW9Bay1xcV9fNXpIVzB4blFCQ0FSQkp0bTlzZTNhMXpOYklUUWNXSjdtZmI2UVl3b1hRX2hHag?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals(RYTM.US) Director Sells US$3.71 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQazRWelIxUmR3akl0X0RCa3ZSVTEteDhmZ0JwV1NYd2xkampINmNQT0c0TGNyRTFpdHRnQklsVmJwLTRKZmJkSS1KNjd6Mk55alZjMEdXWU1lTENlY1hmdVJ3d1RYZnU0NFF1aGxuaVlaM0lMaE5GX01VNWZxQXFrVDFsRFZ0NFowMTdEbmFOWHlFRU55TEZ5ZTdNTVB0eGJaSm9uRVRYSXc?oc=5", "source_name": "Moomoo", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdXRYT2Q3RldYYkE2dnZhaWRFd2ZnV3Zyd3lMa3JHZk5iT2l4eHJIbTZkMEFNLTlTeUtzS0VGSzgtZkVvZ3J5dU5KWmNyMWpVZTdwdjVZSkZiZEphNEhEc2RIZVFKVG5CUjNwT25NbHlNRVY4blktX2xnZ01DV3NNUWIwYkVBckVSd2RRVjR1T2QwTWZsNmg4QUhwNzBqZjdDZkkxQjVuRGd3bENzMTdyMlMyY2RrTTFTYWdxRA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQU0hTczJJLUJRRndBd1BlWkYzRFZUWjhodDI4dGRWX05TOVJtVjN0dWJxVUI0YnVrbnpLMGl0czRzQ3ZEaVU2bXRjSVJESVJJSWNRemxuTks0RVhIZDVSN0xOUnlnbFV1R0ZFN3Z5SzJ4U3N2R1lqbmxrQWlPbXJueGItMTVVVTNpaEJESTF4OUhzSXNWaGpCckdMUUkxdkxOcWlKd0dIMnRjU1U1ZkJ2ZzNXTWVrMDN0N3Z2Z3lDc0I?oc=5", "source_name": "Trefis", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Rhythm Pharmaceuticals (RYTM) \u2019s New Data Help Patients With a Rare Hunger Disorder?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rhythm-pharmaceuticals-rytm-data-help-141500938.html", "source_name": "Insider Monkey", "published_at": "2026-06-22T14:15:00+00:00", "published_display": "22 Jun 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RHYTHM PHARMACEUTICALS, INC. SEC Filing (Jun 22, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOSG5VLWZSY0FpMW5hMU5uVW80eUFSMEE2UGI5N0RubnYzLTRFbUI4VlZmS3ZBNlZ6amVONTBJaVNGTGV4bWlwUzF0dmN1NVRydmcxZkpwb1g4dkNWNHNuWVhBM1E3X25FWnhsOVJ3Ti1LaTU2UDMxelJXZERQNWZvQlh0cmVDZUJ5TkFsY29MYkZwX3RkOWktaUlPRWJsczJVRWJSYW93?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity", "summary": "", "url": "https://finance.yahoo.com/m/a04f1a26-d944-3d53-a27d-549494a3b05b/rhythm-pharmaceuticals-posts.html", "source_name": "Proactive", "published_at": "2026-06-16T15:37:00+00:00", "published_display": "16 Jun 2026 15:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rhythm-pharmaceuticals-announces-multiple-data-200100919.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T20:01:00+00:00", "published_display": "15 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Rhythm Pharma Stock Jumping Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOTUl1SExJOWVCQzdnOW1TU1VHZXBwVmtoVV9aSWptQUxvTlV6enNCY1NxdXNibmJlc21fdXRoaVV1WjlPZVBIdURNTDRoTTMxX3c1YnZpcU1SVWtWaXBPbkp2eDhPVkJrZzVMYWVsVXU1WmMzaGVGeTNCTFNPZGpZRVZnVU9nbkRrNjJqNW5sUkZXc2V1emFKYTBrdXdtZw?oc=5", "source_name": "Benzinga", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rhythm-pharmaceuticals-presents-positive-interim-120100510.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T12:01:00+00:00", "published_display": "13 Jun 2026 12:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQTlc5M25rMmZON0ZGMGxjMXI0MUk0dXpvbnFweVpXSVhKYXpDUXBpcnZsRjlEaGUtWk43bWs0NG0wLWllX0FkYnAtX0FRRUpsX1dUbEZsWTlSSFY1QzczeGNxR3p1VU9FandiWmpER1FGTlppdGFYOUw5SmNFeHFNdC1iOXV0ejRDZlQ2NUdUdW44aVZlQ3A5RmdBYzM1M2NjdGZPNmUxTUhyNXJScVhpaUVqZlI1aWxfM0lqMzEyWHo2dVlKM3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOalFlbWJoWnRObW9hYzlEZmZ6ODloSWk3MkVHOGdQc1FNVndqQ3JnVmM3MjFvSERaQkZEclVBYkJJVGUtVFZSSkUxX3hfejVJTHlad0dkMjZKUFFNZHVEemNzNUpzRDdtVks2bXl3WDQwUUdybDlPa1RtREl5VXdOT2VXbF8wcTVuX3IyMGx2eEtZN2FNX2E1YldQYk5BU0JER3pkdjhn?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its Recent Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNaE1RazE3ZHRCWXJUbnZ0Mm1VXzhCanhKU09mX3B0VnBVcGxvc2ZUZ0lGUERiY1ViT1hoN3l2eUUyUmVxOXZDSFlCMnBTdFN1WTRxc0tQVnZreG1SS2RrRC1YOUkySGw1ZTRRYkg0cnEzbk5kcXRMX3ZPRDlwZW1pUXdHcHpzeEV0OV9RQl9YdDRIQlRLVUdXMXdRRWUyYm1jbWNHN2QxMjRKeldBc21vVkxfd2phd2tTSWRNcHp6aE15eG5yTFpFWG5oR0ZwSTlWQVY3SmcwZ2ZFU2c1TjZINFlEdEg0cGZYXzcxZzc0VdIB9AFBVV95cUxQcUk5MkUwUVlpRGUwa3BLNW4xS2lxSDQ1R0poUGJyTHhUOE1TLUg2YXlPbFBfZThCQ3RHTGVnS2hoUElXM1dZc1MtX1F6V3pfN2c0VG5RanI4alpjOEtUek5JTkVqVERoaXRVTVBIbHcySmJjSjJ3TU5KWGMyUHNIenVaamUtNnk1YlYzX1llVE1obTkyMzN1SE92STZzVkswSWJ4dnlxSm1CWGJ6dzVEeHpSX1BMWDVONnFMTmQwWnF6VUpEUFY2RE1uQVdRSWdPTlE2bWZ4WEZacTRoMTd3aFljZ3lPZk1EeXpRY19kNzlQQ0ZQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Q1 2026 Earnings: Stock Rises 8% on Imcivree Revenue Beat - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPLUoweEFBQzNaQl9WTkVDeHRNM1NuR0ZYeTk3WHNTcHhvR1FjY2pPbkd4VGdGdWd6SS1PaGdyWmFRZkdkMktaWnpjVjJQcXpqTUppQWJacnpmbk9MZldhUGd0T0JycVZmS1Z6UzgzT1pBTFcwVlJZbWp5MnJoUTJTTFprc00tTEpDdzRuUEZpTHQxVFNBMlhtbkpsR3lFZEVRYnpjNENTSFIxZWg3Vnd2eDB3?oc=5", "source_name": "IndexBox", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm CEO to speak at Bank of America healthcare conference May 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOWldWTjVLSmVuVDNRajl3THZfVmFCTXMwQ2xLWTNRZmw0VWR0OFpOMXZUSVp3YXg0VVR3Uy1UTzEtNWpqVmhzNVdjRVZ1YUNjNkNIWmZiQUpSSTFOZnlvNlRyRGFpVGJ6Nk9NVzRsbGxKYVNzVGJ4QVc4YVo5R2VJcTNDUHdQYXRNR01aeFYxSnZKTHhNaEF1QnJHODdITkxNLWJGcHVwdlVQbmVhcGExeE9oa3BDU2VGSHFJSFdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPMUNrcGFWTXluSWtGUEszTzR5UzlVLW80X1c3Y3ViQkR0UW9RWDNvY1BxZjQ1NjdFOWZBUThvUHRZRnBROFp2QzZKLXFIbjhXdXpVQTRNT1gwSEF6T1dfNGRiNHQ3YTl4VktLNG0xVjc3YU5ncDBab2VKVkVGamFWLTR1aXJta0VBTUczVUxuckpYR0VvOG9ncjBLQ0lPdzBzMV9FaXJBeDhzSFRx?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPbS10bWNXQV9JWnA1TWhpTzhmejZxTG1nS1hPanRoVzh2dHpFY3dySExrS3I0V0FsQW80bzNCUzNRbXZCc3g0RG8yTUhCM2RpY240emMzS0xZNG9neU5fekFXb2dMRzNSemttMnYzN0tDVDRSMmI3UmtBYzY3UjRhMXF5ajJwSDl2LTVnZ2lWTjRMdmRLb09FaFF2cjAzZEZfZUM0MFdGeFhqa3BDaUtocVQwUEthRW8wMkoyUHlEb2xaVXlUOFhJQ0xxdk1UYUtlYmNaMm1WSFBJdkxTa2lDUFRHbFI1amlwVmlLZktJWEw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOQkViaHNXNkhrZW9YMmZvbGdsa2o5X0pLaVVpOXlKQ3lCMlE1bDUzTkx1ZnBNRk1uc0hiSnJhUVpNbWZILVNudFotNlhISTY1SHNXOVQ1UldtUDBxeXpjR0pabV8tZUxZb094S1I4NE1fR3NUR0hZV3NWdUF4Y0pHRG9sd24wbWVVRlB3QlJLR2NiY3ZFc1J0MGJ3RjI3QU95R3JpRlU5OWRuZjJGS1pSdEs4bm4?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQZjdSMGR4aUtzbnN3RWdoV1hDZlVoWV9XdWFKckZYRldpenVpSFF6M2l2UEVKV1lrRGwzSE93M2dfOFNGenQ5cHYxcGs5UHQyVlR6cXh0TEtibGR3eDg0akhEUmVPcWNEcHhCLUR6d0w2TFNyX0t0WXFBeFNMQXFIc256REp2WDZDRzEzLTBiRkZoUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxNRGwxUzVxcHFDcTdBLXNvVjcwdG9PLU1Pdmpram1RUHdHOFdoRFd4Vm1xM0xhVEszcTZiTE5zSTZ4WGZVbWtaUW9ucFR4aWxqLThES19DUXdkdlBuUXlDS3dlUmh6X1Brdjc4cjhxMUJnV25kbVBEUk5fdHdNYmZNZ0pod0lhOVpiVXFyWnJEZ3NMUXItb051TjlGYldYRmswZURTUEpvUUwwMm9sSFR1N3J3MlExa08wVDhVOWxwSGhZMzU2ZWtrSmltd01HNXRXbGg0M1dqRUtmZjA5SldHcnFMdjZLYTJJbUlwMUZ2Vzd4UEhEajNiajN4WVBFY1k3?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q2 2025 Rhythm Pharmaceuticals Inc Earnings Call Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5EQWFaQ0pmbWdqWWdGNnVsMHFabFhhQlBaUU5tbk55U1BtblpzSENKZm5oVzQ4OFl2Z0k0NDBfd2otaVl1Ml9IRlFyeWJUc3Q2VHpNTkk3RkY5TnFDbkhONGl1Z1o0X2JXcVVQeQ?oc=5", "source_name": "GuruFocus", "published_at": "2025-08-05T07:00:00+00:00", "published_display": "05 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 59, "sentiment_summary": {"positive": 22, "negative": 4, "neutral": 33, "score": 57, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 77, "events": [{"event": "earnings", "label": "Earnings", "weight": 15.26, "count": 30}, {"event": "general", "label": "Market update", "weight": 12.45, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 22, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 106.6, "latest_week": "2026-07-17", "one_week_move": -1.7, "four_week_move": 10.1, "twelve_week_move": 24.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.217937, "market_dynamics_buy_signal": false, "relative_strength": -2.574997, "fair_value_gap": 67.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.2112, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.7% over one week, +10.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "DirectorsTalk Interviews", "count": 2}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 30}, {"label": "Market update", "count": 22}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.7% over one week, +10.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm"}], "updated_at": "2026-07-22T11:44:15.146925+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}